Kanker-actueel Tamoxifen and radiotherapy: Tackling breast cancer with tamoxifen after surgery and radiation in women over 70 years seems pointless. For women aged 50 years, this approach is sensible for local metastases.

Startpagina

Contact | Disclaimer | Sitehulp

Sitemap | Video's

Patiëntenervaringen | Lotgenotencontact

Forum |

Onze Sponsors

Cancer Types

Regular

Complementary

Coaching

Donations

Questions

Cancer News

Addresses

Prevention

Recipes

Artikelen

Arimidex - anastrozole information and study overview

Breast Cancer: Exemestane Exemestane = gives much better effect on overall survival and disease-free and reduced risk of recurrence than tamoxifen so large phase III study. Article updated March 28, 2011

Breast Cancer: Exemestane Exemestane = drug approved by FDA as a treatment for women with breast cancer at the age of the transfer.

Femara: Information on proven effectiveness and use of Femara - Letrozole in breast cancer put together.

Breast cancer: Femara - gives letrozole in women with breast cancer five years tamoxifen who have used a significantly longer disease-free time but not significantly better overall survival compared to placebo.

Hormones: Injections of goserelin - Zoladex given alongside chemotherapy in women with breast cancer who are menstruating completely protect ovaries. Freezing seems better alternative. Article updated August 3, 2011

Hormones: Women who take hormone treatments to counter disadvantages of transition have significantly higher risk of breast cancer and more serious nature of breast cancer, said major long-term study of WHI - Women's Health Initiative

Breast cancer: Hormones in breast cancer: Hormone therapy and during the transition caused 54-93% chance galwegziekte so randomized study of more than 14,000 healthy women.

Hormone therapy: After two to three years to switch from tamoxifen to Arimidex provides significantly less risk of a recurrence of breast cancer, two large randomized trials with a duration of three years.

Hormones: Breast cancer patients who survive hormone treatments / aromaseremmers such as Letrazole - Femara and Arimidex - Anastrazole or survive with the help of chemotherapy experienced still greater risk of osteoporosis = osteoporosis in later life. Tamoxifen causes less osteoporosis later in life than the newer hormone treatments / aromaseremmers which in turn is significantly better effect on the breast itself. Read study abstract explanatory article, osteoporosis and breast cancer in alphabetical list. Article updated August 3, 2011

BRCA1 and BCRA2: Prophylactic mastectomy (preventive surgery of breasts) and salpingo-oophorectomy (removal of ovaries, fallopian tubes plus) in women with BRCA1 and BRCA2 mutation works great at preventing breast cancer and ovarian cancer. Shows a large long-term study of 2500 women and BCRA1 BCRA2 mutation. Article posted September 2, 2010

Red clover isoflavones are not significantly improved bone density on mammography than placebo, significantly better than conventional hormone therapy for women with breast cancer so randomized phase III study. Article updated March 28, 2011

Tamoxifen: Tamoxifen use in breast cancer patients in addition to the antidepressant paroxetine are more likely to die prematurely. This shows a 12 year population in Canada in 2430 women over 66 years with breast cancer. Article posted February 10, 2010

Tamoxifen and radiotherapy: Tackling breast cancer with tamoxifen after surgery and radiation in women over 70 years seems pointless. For women aged 50 years, this approach is sensible for local metastases, although again no difference in getting remote metastasis and survival between the two groups, according to recently published randomized trials. Article updated March 28, 2011.

Tamoxifen: Surgery in older women with breast cancer followed by tamoxifen provides no difference in survival than tamoxifen alone, says five-year randomized study in 476 women. Article updated July 12, 2011

Tamoxifen: Tamoxifen information put together.

Aromasin - Exemestane produces slightly better results in postmenopausal women with breast cancer than Arimidex - Anastrazole but not significantly. Or offers to switch from Arimidex to Aromasin if that fails to catch on more opportunities than the other way. Article posted August 3, 2011

Everolimus (Afinitor) with exemestane provides significantly longer disease-free time for women with hormone sensitive breast cancer, even where there was resistance to Arimidex and Femara. Article posted September 27, 2011

Tamoxifen and radiotherapy: Tackling breast cancer with tamoxifen after surgery and radiation in women over 70 years seems pointless. For women aged 50 years, this approach is sensible for local metastases, although again no difference in getting remote metastasis and survival between the two groups, according to recently published randomized trials. Article updated March 28, 2011.

March 28, 2011: NAV 2004 following studies already see among others, are the most recent study into the use of tamoxifen and radiation for early breast cancer: DICS - ductal in situ from March 2011

September 9, 2004: Source: PubMed: N Engl J Med. 2004 September 2, 351 (10) :971-7.

Randomized studies have shown that women with breast cancer over 70 years operation and tamoxifen is as effective as surgery and radiation and tamoxifen and with no additional irradiation seems postief effect for women older than 70 years. Another randomized study shows this approach in women over 50 years have a significant positive effect on local recurrence. Irradiation provides additional side effects and is of course much more intensive for the patient.

In the study in women over 70 years to five years was no difference observed between the two groups. In the study in women aged 50 years show the difference significantly better on whether to get local metastases. Both studies also no difference in whether or not to get remote metastases and no difference in survival. In the study of women aged 50 years, there was no difference in survival between women who have breast cancer and women who were not further irradiated. Moreover, several studies have shown that other hormone treatments, and better than tamoxifen efectiever. See more information about under -breast cancers . Perhaps with good diet and some extra vitamins and minerals and anti-oxidant effect of these treatments are improving, but before you have to do a consultation with a qualified orthomolecular doctor. Thus, for example, a study found that GLA is many in evening primrose oil to supplement the effect of radiation appears to increase the side effects and significantly. Read study report of GLA under tamoxifen

Here are the abstracts of both studies taken from Pubmed and published with notes, etc. New England Journal of Medicine in September 2004.

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.

Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC , Norton L, Cancer and Leukemia Group B, Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group.

Avon Comprehensive Breast Evaluation Center, Breast / Ovarian Cancer Genetics and Risk Assessment Program, Massachusetts General Hospital, Division of Surgical Oncology, Boston 02114, USA. kshughes@partners.org

BACKGROUND: In women 70 years of age or older who have early breast cancer, it is Unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy.

METHODS: Between July 1994 and February 1999, we randomly Assigned 636 women who were 70 years of age or older and who had clinical stage I (T1N0M0 According To the tumor-node-metastasis classification), estrogen receptor-positive breast carcinoma Treated by lumpectomy plus radiation therapy to receive tamoxifen (317 women) or tamoxifen alone (319 women). Primary end points were the time to local or regional recurrence, the frequency of mastectomy for recurrence, breast-cancer-specific survival, the time to distant metastasis, and overall survival.

RESULTS: The only significant difference Between the two groups was the rate of local recurrence at five years or regionalism (1 percent in the tamoxifen plus irradiation group Given and 4 percent in the tamoxifen group Given alone, P <0.001). There were no significant differences with regard Between the two groups to the rates of mastectomy for local recurrence, distant metastases, or five-year rates of overall survival (87 percent in the tamoxifen plus irradiation group Given and 86 percent in the tamoxifen group, P = 0.94). Assessment by physicians and patient or cosmetic results and adverse events uniformly rated tamoxifen plus irradiation inferior to tamoxifen alone.

CONCLUSIONS: lumpectomy plus adjuvant therapy with tamoxifen alone is a realistic choice for the treatment of women 70 years of age or older who have early, estrogen-receptor-positive breast cancer. Copyright 2004 Massachusetts Medical Society

Source: PubMed: N Engl J Med. 2004 September 2, 351 (10) :963-70.

Tamoxifen With or Without breast irradiation in women 50 years of age or older with early breast cancer.> Br>
Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, Weir LM, Olivotto IA.

Department of Radiation Oncology, Princess Margaret Hospital, Toronto,ON, Canada. <a Href="mailto:anthony.fyles@rmp.uhn.on.ca> anthony.fyles @ rmp.uhn.on.ca

BACKGROUND: We Determined the effect of breast irradiation plus tamoxifen on disease-free survival and local relapse in women 50 years of age or older who had T1 or T2 node-negative breast cancer.

METHODS: Between December 1992 and June 2000, 769 women with early breast cancer (tumor diameter, 5 cm or less) were randomly receive breast irradiation plus Assigned to tamoxifen (386 women) or tamoxifen alone (383 women). The median follow-up was 5.6 years.

RESULTS: The rate of local relapse at five years was 7.7 per cent in the Tamoxifen group and 0.6 per cent in the Group Given Tamoxifen plus irradiation (hazard ratio, 8.3; 95 percent confidence interval, 3.3 to 21.2, P <0.001), with corresponding thing five -year disease-free survival rates of 84 percent and 91 percent (P = 0.004). A planned subgroup analysis of 611 women with T1, receptor-positive tumors benefit from a Indicated radiotherapy (five-year rates of local relapse, 0.4 percent with tamoxifen plus radiotherapy and 5.9 percent with tamoxifen alone, P <0.001). Overall, there was a significant difference in the rate of axillary relapse at five years (2.5 percent in the tamoxifen group and 0.5 percent in the tamoxifen plus irradiation group Given, P = 0.049), but no significant difference in the rates of distant relapse or overall survival.

CONCLUSIONS: As compared with tamoxifen alone, radiotherapy plus tamoxifen significantly Reduces the risk of breast and axillary recurrence after lumpectomy in women with small, node-negative, hormone receptor-positive breast cancers. Copyright 2004 Massachusetts Medical Society